Institute for Immunology and School of Medicine, Tsinghua University, Beijing, China.
Front Immunol. 2022 May 10;13:887189. doi: 10.3389/fimmu.2022.887189. eCollection 2022.
Dendritic cells (DCs), the strongest antigen-presenting cells, are a focus for orchestrating the immune system in the fight against cancer. Basic scientific investigations elucidating the cellular biology of the DCs have resulted in new strategies in this fight, including cancer vaccinology, combination therapy, and adoptive cellular therapy. Although immunotherapy is currently becoming an unprecedented bench-to-bedside success, the overall response rate to the current immunotherapy in patients with gastrointestinal (GI) cancers is pretty low. Here, we have carried out a literature search of the studies of DCs in the treatment of GI cancer patients. We provide the advances in DC-based immunotherapy and highlight the clinical trials that indicate the therapeutic efficacies and toxicities related with each vaccine. Moreover, we also offer the yet-to-be-addressed questions about DC-based immunotherapy. This study focuses predominantly on the data derived from human studies to help understand the involvement of DCs in patients with GI cancers.
树突状细胞（DCs）是最强的抗原呈递细胞，是协调免疫系统对抗癌症的焦点。阐明 DC 细胞生物学的基础科学研究为这场斗争带来了新的策略，包括癌症疫苗学、联合治疗和过继细胞疗法。尽管免疫疗法目前正在成为前所未有的从实验室到临床的成功，但胃肠道（GI）癌症患者对当前免疫疗法的总体反应率相当低。在这里，我们对 DC 治疗 GI 癌症患者的研究进行了文献检索。我们提供了基于 DC 的免疫疗法的进展，并强调了表明与每种疫苗相关的治疗效果和毒性的临床试验。此外，我们还提供了关于基于 DC 的免疫疗法的尚未解决的问题。本研究主要侧重于从人体研究中得出的数据，以帮助了解 DC 在胃肠道癌症患者中的参与。
